• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Extended release quetiapine fumarate in patients with major depressive disorder: Suicidality data from acute and maintenance studies
【24h】

Extended release quetiapine fumarate in patients with major depressive disorder: Suicidality data from acute and maintenance studies

机译：延长释放Quetiapine富马酸核患者主要抑郁症：来自急性和维护研究的自由性数据

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To prospectively analyze effects of extended release quetiapine fumarate (quetiapine XR) on suicidality in major depressive disorder (MDD). Method: Data were pooled from randomized, acute studies (4 monotherapy; 2 adjunct therapy) in adult patients with a DSM-/l^diagnosis of MDD who were considered not to be at high risk of suicide at baseline and were receiving quetiapine XR 50 mg/d (n = 181), 150 mg/d (n = 910), or 300 mg/d (n=685) or placebo (n = 957). Data from 1 acute monotherapy study in elderly patients receiving quetiapine XR (50-300 mg/d; n = 166) or placebo (n = 172) and maintenance data (up to 52 weeks) for patients receiving quetiapine XR (50-300 mg/d; n = 391) or placebo (n = 385) were also evaluated. Overall incidences and relative risks for suicidality (suicidal behavior/ideation) were assessed by Columbia-type review and classification. The proportion of patients with Montgomery-Asberg Depression Rating Scale (MADRS) item 10 (suicidal thoughts) score ≥4 was analyzed. Results: Incidence of suicidality during acute treatment in adults was 1.1 %, 0.7%, 0.7%, and 0.7% with quetiapine XR 50 mg/d, 150 mg/d, and 300 mg/d and placebo, respectively. The proportion of patients with MADRS item 10 score ≥ 4 during acute treatment in adults was 1.8% with quetiapine XR (all doses combined) and 2.4% with placebo. In elderly patients, the incidence of suicidality during acute treatment was 0.6% in both treatment groups; the proportion of patients with MADRS item 10 score ≥4 was 0% with quetiapine XR (all doses combined) and 1.2% with placebo. During maintenance treatment, the incidence of suicidality was 0.3% (n = 1) and 0.5% (n = 2) for quetiapine XRand placebo, respectively. The proportion of patients with MADRS item 10 score ≥ 4 was 4.1 % with quetiapine XR in the open-label stabilization period and 0.3% with quetiapine XR and 0.5% with placebo during the randomized period.
机译：目的：探讨延长释放喹硫氏菌富马酸核苷酸（喹硫甙XR）对重大抑郁症（MDD）的自杀的影响。方法：从随机，急性研究（4个单一疗法; 2个申请治疗）汇集了数据的DSM- / L ^诊断MDD的诊断，他们被认为是基线自杀的高风险，并接受Quetiapine XR 50 Mg / d（n = 181），150mg / d（n = 910），或300mg / d（n = 685）或安慰剂（n = 957）。 1患者1急性单药治疗的数据从老年患者接受血糖XR（50-300mg / d; n = 166）或安慰剂（n = 172）和接受血管XR的患者的维持数据（最多52周）（50-300毫克/ d; n = 391）或安慰剂（n = 385）也得到评价。通过哥伦比亚型审查和分类评估了自由性的整体事件和相对风险（自杀行为/思想）。分析了蒙哥马利 - Asberg抑郁率（Madrs）第10项（自杀思想）评分≥4患者的比例。结果：成人急性治疗过程中的自杀发生率为1.1％，0.7％，0.7％和0.7％，分别分别与喹诗XR 50mg / d，150mg / d和300mg / d和安慰剂。在成人急性治疗期间MADRS项目10分数≥4的比例为1.8％，喹啉XR（所有剂量组合）和安慰剂的2.4％。在老年患者中，两种治疗组中急性治疗期间的自杀发病率为0.6％; MADRS项目10分数≥4患者的比例为0％，喹啉XR（全剂量组合）和安慰剂的1.2％。在维持治疗期间，分别的自由性的发生率为0.3％（n = 1）和0.5％（n = 2），用于喹啉Xrand安慰剂。 MADRS项目10分数≥4的比例为4.1％，在开放标签稳定期中，喹甲酸XR在随机期间，随机血管XR喹啉XR和0.5％的安慰剂。

著录项

  • 来源
  • 作者

    WeislerR.; MontgomeryS.A.; EarleyW.R.; SzamosiJ.; ErikssonH.;

  • 作者单位

    Department of Psychiatry University of North Carolina at Chapel Hill Durham NC United States;

    Department of Psychiatry Imperial College University of London London United Kingdom;

    AstraZeneca Pharmaceuticals Wilmington DE United States;

    AstraZeneca Research and Development S?dert?lje Sweden;

    AstraZeneca Research and Development S?dert?lje Sweden;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 精神病学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号